Close Menu

NEW YORK (360Dx) – Australian proteomics firm Proteomics International said today it is collaborating with Janssen Research & Development to use its PromarkerD test for diabetic kidney disease in drug development.

Under the terms of the agreement, the companies will evaluate the performance of the PromarkerD test for predicting decline in kidney function and drug response in patients from Janssen's clinical trials. The companies will also look at whether PromarkerD is useful for predicting heart disease.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.